ANI Pharmaceuticals acquires NDAs and US marketing rights for ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX
2 January 2018 -

ANI Pharmaceuticals Inc (Nasdaq: ANIP), an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, has acquired the NDAs and United States rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca, an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.

It was reported on Friday that the deal is valued at USD46.5m in cash, royalties, and sales-based milestones.

AstraZeneca will continue to market and supply the products outside the United States. The acquired assets include the NDAs for all four products and a license to their trademarks. The acquisitions were funded through a combination of cash and debt.

ATACAND, ATACAND HCT are hypertension drugs, while ARIMIDEX, and CASODEX are for the treatment of breast cancer and prostate cancer respectively.